BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12420210)

  • 1. The effect of post-transplant spironolactone on daily potassium requirements in patients undergoing autologous stem cell transplantation.
    Demirer T; Ayli M; Dagli M; Fen T; Haznedar R; Ustael N; Ustun T; Oymak A; Ozdel O; Muftuoglu O
    Bone Marrow Transplant; 2002 Nov; 30(10):703-4. PubMed ID: 12420210
    [No Abstract]   [Full Text] [Related]  

  • 2. Autologous stem-cell transplantation can be performed safely without the use of blood-product support.
    Ballen KK; Becker PS; Yeap BY; Matthews B; Henry DH; Ford PA
    J Clin Oncol; 2004 Oct; 22(20):4087-94. PubMed ID: 15353543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of spironolactone on urinary calcium excretion.
    Ben-Ishay D; Viskoper RJ; Menczel J
    Isr J Med Sci; 1972 Apr; 8(4):495-501. PubMed ID: 5034800
    [No Abstract]   [Full Text] [Related]  

  • 4. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.
    Baron F; Frère P; Fillet G; Beguin Y
    Clin Cancer Res; 2003 Nov; 9(15):5566-72. PubMed ID: 14654537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation.
    Staber PB; Holub R; Linkesch W; Schmidt H; Neumeister P
    Bone Marrow Transplant; 2005 May; 35(9):889-93. PubMed ID: 15765110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot randomised double-blind controlled trial of high-dose spironolactone in critically ill patients receiving a frusemide infusion.
    Apte Y; Bellomo R; Warrillow S; Goldsmith D; Gillies M; McGain F
    Crit Care Resusc; 2008 Dec; 10(4):306-11. PubMed ID: 19049481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell large granular lymphocytic leukemia occurring after autologous peripheral blood stem cell transplantation.
    Narumi H; Kojima K; Matsuo Y; Shikata H; Sekiya K; Niiya T; Bando S; Niiya H; Azuma T; Yakushijin Y; Sakai I; Yasukawa M; Fujita S
    Bone Marrow Transplant; 2004 Jan; 33(1):99-101. PubMed ID: 14704662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced hemoglobin on day of peripheral blood progenitor cell collection is associated with low graft content of vascular progenitors and increased toxicity after autologous hematopoietic stem cell transplantation.
    Kasbia G; Al-Gahtani F; Tay J; Labonté L; Tinmouth A; Ramsay T; Gillingham A; Yang L; Halpenny M; Giulivi A; McDiarmid S; Huebsch L; Allan DS
    Transfusion; 2008 Nov; 48(11):2421-8. PubMed ID: 18673346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow failure associated with herpesvirus 8 infection in a patient undergoing autologous peripheral blood stem cell transplantation.
    Cuzzola M; Irrera G; Iacopino O; Cuzzocrea A; Messina G; Console G; Iacopino P; Morabito F
    Clin Infect Dis; 2003 Oct; 37(7):e102-6. PubMed ID: 13130419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation.
    Orlent H; Crawley C; Cwynarski K; Dina R; Apperley J
    Bone Marrow Transplant; 2003 Jul; 32(1):115-7. PubMed ID: 12815488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual quality of life of patients undergoing autologous peripheral blood stem cell transplantation.
    Frick E; Borasio GD; Zehentner H; Fischer N; Bumeder I
    Psychooncology; 2004 Feb; 13(2):116-24. PubMed ID: 14872530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial.
    Valteau-Couanet D; Faucher C; Aupérin A; Michon J; Milpied N; Boiron JM; Bourhis JH; Gisselbrecht C; Vernant JP; Pinna A; Bendahmane B; Delabarre F; Benhamou E
    Bone Marrow Transplant; 2005 Sep; 36(6):547-52. PubMed ID: 16007101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CARES-SF used for prospective assessment of health-related quality of life after stem cell transplantation.
    Hjermstad MJ; Evensen SA; Kvaløy SO; Loge JH; Fayers PM; Kaasa S
    Psychooncology; 2003 Dec; 12(8):803-13. PubMed ID: 14681953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation.
    Cairoli R; Grillo G; Tedeschi A; D'Avanzo G; Marenco P; Morra E
    Haematologica; 2004 Mar; 89(3):361-3. PubMed ID: 15020279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptom burden in patients undergoing autologous stem-cell transplantation.
    Anderson KO; Giralt SA; Mendoza TR; Brown JO; Neumann JL; Mobley GM; Wang XS; Cleeland CS
    Bone Marrow Transplant; 2007 Jun; 39(12):759-66. PubMed ID: 17438588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome.
    González-Vicent M; Ramírez M; Sevilla J; Pérez A; Fernández S; Madero L; Díaz MA
    Bone Marrow Transplant; 2004 Dec; 34(12):1051-5. PubMed ID: 15516943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood stem cell transplant: a multicenter project.
    Dettenkofer M; Wenzler-Röttele S; Babikir R; Bertz H; Ebner W; Meyer E; Rüden H; Gastmeier P; Daschner FD;
    Clin Infect Dis; 2005 Apr; 40(7):926-31. PubMed ID: 15824981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mobilization of PML-RARA negative blood stem cells and salvage with autologous peripheral blood stem cell transplantation in children with relapsed acute promyelocytic leukemia.
    Termuhlen AM; Klopfenstein K; Olshefski R; Rosselet R; Yeager ND; Soni S; Gross TG
    Pediatr Blood Cancer; 2008 Oct; 51(4):521-4. PubMed ID: 18493994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation.
    Villela L; Sureda A; Canals C; Sanz MA; Martino R; Valcárcel D; Altés A; Briones J; Gómez M; Brunet S; Sierra J
    Haematologica; 2003 Mar; 88(3):300-5. PubMed ID: 12651269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation.
    Demirer T; Uysal VA; Ayli M; Genc Y; Ilhan O; Koc H; Dagli M; Arat M; Gunel N; Fen T; Dincer S; Ustael N; Yildiz M; Ustun T; Seyrek E; Ozet G; Muftuoglu O; Akan H
    Bone Marrow Transplant; 2003 May; 31(9):755-61. PubMed ID: 12732881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.